Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Kazakhstan has been experiencing steady growth in recent years.
Customer preferences: Patients suffering from rheumatic diseases in Kazakhstan have been showing a growing preference for biologic drugs over traditional disease-modifying antirheumatic drugs (DMARDs). This is due to the higher efficacy of biologics in treating rheumatic diseases and their ability to slow down the progression of the disease.
Trends in the market: The Anti-Rheumatic Drugs market in Kazakhstan has been growing steadily due to the increasing prevalence of rheumatic diseases in the country. The aging population and changing lifestyles have contributed to the rise in the incidence of these diseases. The market has also been driven by the increasing availability of biologic drugs in the country. The government has been taking steps to improve the availability of these drugs by including them in the list of reimbursable drugs.
Local special circumstances: Kazakhstan has a high burden of rheumatic diseases, with over 500,000 people suffering from these diseases in the country. The government has been taking steps to improve the diagnosis and treatment of these diseases by establishing specialized centers for rheumatology. However, the availability of specialized healthcare services is still limited in some parts of the country, which has led to disparities in the quality of care for patients.
Underlying macroeconomic factors: The healthcare sector in Kazakhstan has been growing rapidly in recent years, driven by government initiatives to improve healthcare services in the country. The government has been investing heavily in the healthcare sector, with a focus on improving infrastructure and increasing the availability of drugs and medical equipment. The country's growing economy and increasing disposable income have also contributed to the growth of the Anti-Rheumatic Drugs market in Kazakhstan, as patients are able to afford more expensive treatments.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
